Treatment of B-cell lymphoma with microRNA
The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are based on the observation that microRNA-34a shows strong anti-proliferative effects when overexpressed in diffuse large B-cell lymphoma (gDLBCL) cell lines, or when delivered intratumorally or systemically in xenograft models of DLBCL.
1. A method of treating a B-cell lymphoma characterized by over-expression of Myc, comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising: (a) a synthetic oligonucleotide duplex comprising a first oligonucleotide strand consisting of a miR-34 sequence selected from the group consisting of: microRNA-34a (SEQ ID NO: 1), microRNA-34b (SEQ ID NO: 2), microRNA-34c-5p (SEQ ID NO: 3), and microRNA-34c-3p (SEQ ID NO: 4), and a second oligonucleotide strand comprising a sequence that is complementary to the first strand; and (b) a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the second oligonucleotide strand has a chemically modified nucleotide.
3. The method of claim 2 , wherein the chemically modified nucleotide is a 2′-O-methylpurine, or a 2′-O-fluoropyrimidine.
4. The method of claim 1 , wherein the synthetic oligonucleotide is bound at the 3′ hydroxy group to a cholesterol.
5. The method of claim 1 , wherein the composition comprises a liposome.
6. The method of claim 5 , wherein the liposome is a pegylated liposome.
7. The method of claim 1 , wherein the composition comprises a neutral lipid emulsion.
8. The method of claim 1 , further comprising administering a second anticancer therapeutic agent to the patient.
9. The method of claim 8 , wherein the second anticancer therapeutic agent is cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/prednisolone, rituximab, or combinations thereof.
10. The method of claim 1 , wherein administering the composition comprises intratumoral, subcutaneous, intravenous, intrahepatic, or intramuscular administration.
11. The method of claim 1 , wherein the B-cell lymphoma is selected from the group consisting of gastric B-cell lymphoma, non-gastric diffuse large B-cell lymphoma, extranodal diffuse large B-cell lymphoma, Burkitt lymphoma and chronic lymphocytic leukemia.
12. The method of claim 1 , wherein B-cell lymphoma is high-grade gastric diffuse large B-cell lymphoma.